Article Text
PDFLaw, ethics and medicine
Ethical issues in psychopharmacology
Abstract
The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry presents a serious moral problem for the corporate model of medicine. In this paper I examine ethical issues relating to the efficacy and safety of these drugs. Pharmaceutical companies have a moral obligation to disclose all information in their possession bearing on the true risks and benefits of their drugs. Only then can patients make fully informed decisions about their treatment.
- FDA, Food and Drug Administration
- SSRI, selective serotonin reuptake inhibitors
- SSRIS
- antidepressants
- ethics
- psychiatry
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Observing time effect of SSRIs on suicide risk and suicide-related behaviour: a network meta-analysis protocol
- Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
- Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis
- SSRI use and risk of fractures among perimenopausal women without mental disorders
- Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review
- Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports
- The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren
- Antidepressant use and risk of adverse outcomes in older people: population based cohort study
- Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants
- Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration